In recent studies, it has been found that long-term remission of multiple sclerosis can be caused by stem cell transplants. Many worked on this study, including Dr. Shiva Gopal Vasishta, a doctor of neurology and psychiatry in Voorhees, New Jersey. Before conducting this trial, Dr. Gopal Vasishta graduate from Government Medical College, completed his residency at Boston City Hospital, and works at Eastern Neurodiagnostic Associates.
Shiva Gopal Vasishta, MD specializes in both Neorology and Psychiatry, and his practice is affiliated with Kennedy Health System Cherry Hill Campus. He supports both English and Spanish, is board certified in Neurology, and accepts a number of insurance plans, including but not limited to Medicare, Humana, and Horizon Blue Cross Blue Shield. This doctor of Neurology desires to give his patients the greatest care that he can offer.
This desire fueled the study, called HALT-MS, which looked at the cases of a number of patients who received a certain treatment which was called high-dose immunosuppresive therapy and autologous hematopoietic cell transplant (HDIT/HCT). It was found that within five years, only 69% of the patients who received this treatment had no relapses in multiple sclerosis or any other disabilities, while those who received it as a long-term treatment were more likely to develop these symptoms.
This trial, conducted by the immune Tolerance Network (ITN) conducted this trial in order to help prevent disability in more patients and give them the quality of life that they deserve. Funded by the National Institute of Allergy and Infectious Diseases (NIAID), it was ensured that those who did the research conducted safe trials on volunteer participants in the hopes of preventing problems for others in the future of their practices. For more information on the proceedings and results of this project and its related phases, visit ClinicalTrials.gov.